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S U M M A R Y
Objective: This study evaluated inducible protein 10 (IP-10) as a diagnostic biomarker for speciﬁc
tuberculosis (TB) infection and evaluated the ability of IP-10 to distinguish between active TB and latent
TB infection (LTBI).
Methods: Forty-six patients with active pulmonary TB, 22 participants with LTBI, and 32 non-TB controls
were enrolled separately. We measured IP-10 in serum and in supernatants from whole blood stimulated
with TB-speciﬁc antigens.
Results: TB antigen-dependent IP-10 secretion was signiﬁcantly increased in the active TB patients and
LTBI subjects compared with controls, but did not differ signiﬁcantly between the active TB patients and
LTBI subjects. Serum IP-10 levels were higher in active TB than in LTBI (174.9 vs. 102.7 pg/ml, p = 0.002).
The respective rates of positive responders of TB antigen-dependent IP-10 were 97.8%, 90.9%, and 12.5%
in active TB, LTBI, and non-TB controls, respectively. For serum IP-10, 87.5%, 45.5%, and 9.5% of
responders were positive in the respective groups.
Conclusions: The IP-10 response to TB antigen may constitute a speciﬁc biomarker for TB infection, but
does not by itself distinguish between active TB and LTBI. Serum IP-10 may enhance the diagnostic
performance when used in combination with another marker.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd.
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Despite the global effort to reduce the burden of tuberculosis
(TB), TB is the highest infectious cause of mortality and morbidity
worldwide, with 1.7 million deaths and 9.4 million incident cases
in 2009 alone.1 Efforts to reduce the TB burden are linked to the
development of rapid diagnostic tests for infection with Mycobac-
terium tuberculosis. The interferon-g (IFN-g) release assay (IGRA), a
recently developed immunodiagnostic test for TB, is available as
the QuantiFERON-TB Gold In-Tube Assay (QFT-GIT; Cellestis,
Australia) and the T-SPOT.TB test (Oxford Immunotec, UK).
Compared with the tuberculin skin test (TST), the IGRA is less
inﬂuenced by the bacille Calmette–Gue´rin (BCG) vaccine and
environmental mycobacterial exposure.2 However, its sensitivity
is suboptimal in immunocompromised patients, and it is unable to
discriminate between active TB and latent TB infection (LTBI).3,4
The sensitivity of the IGRA can be enhanced by using alternative or
additional biomarkers. In this context, IFN-g-inducible protein 10
(IP-10) has been extensively studied in both adults and children.5–9* Corresponding author. Tel.: +82 2 2228 1986; fax: +82 2 393 6884.
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http://dx.doi.org/10.1016/j.ijid.2012.07.013IP-10 is produced primarily by monocytes/macrophages and
has a role in trafﬁcking of Th1 lymphocytes to inﬂamed foci
through an interaction with a CXC chemokine receptor.10 High
levels of IP-10 were found in the pleural effusion and lung
tuberculosis granuloma of TB patients.11 Previous studies have
reported that IP-10 expression following stimulation with M.
tuberculosis-speciﬁc antigens is a promising biomarker with high
sensitivity for the immunodiagnosis of TB infection.5,6 In contrast
to IFN-g, IP-10 expression in response to TB-speciﬁc antigen was
not inﬂuenced by the ability to respond to mitogens or by the CD4
cell number in HIV-infected patients.12,13 However, there have
been discordant results regarding whether IP-10 can distinguish
between active TB and LTBI. Plasma levels of IP-10 were higher in
active TB than in LTBI and showed a reduction at the end of M.
tuberculosis treatment.14 In addition, baseline plasma IP-10 and
CFP-10-stimulated IP-10 levels were signiﬁcantly higher in active
TB than in LTBI in patients with rheumatoid arthritis.15 Conversely,
TB-speciﬁc antigen-stimulated IP-10 could not distinguish be-
tween active TB and LTBI in children diagnosed by IGRA.7,16
This study evaluated IP-10 as a diagnostic biomarker for speciﬁc
TB infection in comparison with the QFT-GIT in Korea, a country
where the incidence of TB is intermediate (70–90/100 000 patients
per year). The ability of IP-10 to distinguish between active TB and
LTBI was also evaluated. Ltd. Open access under the Elsevier OA license.
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2.1. Study population
Participants were recruited from November 2010 to March 2012
in Severance Hospital, a tertiary referral hospital in South Korea,
after the protocol had been approved by the Ethics Review
Committee. Eligible subjects consenting to the study were recruited
into three groups: active TB, LTBI, and non-TB control groups. The
active TB group consisted of patients with active pulmonary TB. The
diagnosis was conﬁrmed by culturing M. tuberculosis from
respiratory specimens. Individuals with HIV infection, end-stage
renal disease, or leukemia/lymphoma, and those who had received
anti-TB therapy for more than 2 weeks or immunosuppressive
therapy, including anti-cancer chemotherapy for malignant disease,
within 3 months of enrollment, were excluded from the study. For
the LTBI group, household contacts with a positive TST who had lived
with a microbiologically conﬁrmed active pulmonary TB patient for
longer than 1 month, were recruited. The non-TB control group
consisted of healthy adults with a negative TST, who were free of TB
symptoms and did not have any contact with active pulmonary TB
patients. Participants in the LTBI and non-TB control groups were
excluded if they showed clinical symptoms or had abnormal chest X-
rays. All study subjects gave informed consent to the use of the
samples obtained.
2.2. Diagnostic tests
2.2.1. Tuberculin skin test
A TST was performed by intradermal injection of 2 tuberculin
units of puriﬁed protein derivative (PPD, RT23; Statens Serum
Institute, Copenhagen, Denmark) using the Mantoux method. The
induration was measured 48–72 h later, using a cut-off of 10 mm
for positivity in immunocompetent subjects.
2.2.2. QuantiFERON-TB Gold In-Tube (QFT-GIT) assay
The QFT-GIT assay was performed in accordance with the
manufacturer’s instructions. Brieﬂy, 1 ml of whole blood was
collected in each of three tubes pre-coated with saline (control), M.
tuberculosis-speciﬁc antigen (ESAT-6, CFP-10, and TB7.7), orTable 1
Demographic and clinical characteristics of the subjects enrolled in the study
Characteristic Active TB group
(n = 46)
Age, years, median (range) 30 (22–74) 
Gender, male/female 21/25 
BMI, kg/m2, median (IQR) 20.73 (18.9–23.2) 
Presence of BCG scar, n (%) 25 (54.3) 
Prior TB treatment, n (%) 5 (10.9) 
Co-morbidity, n (%)
Hypertension 2 (4.3) 
Diabetes mellitus 3 (6.5) 
Othera 5 (10.9) 
Pulmonary TB diagnosis, n (%)
AFB smear, positive 9 (19.6)
AFB culture, positive 37 (80.4)
Extent of lesion in pulmonary TB, n (%)
One-third of lung ﬁeld 21 (45.7%)
One-half of lung ﬁeld 20 (43.5%)
More than half of lung ﬁeld 5 (10.9%)
Combined extrapulmonary lesion, n (%) 2 (4.3%)
TST induration, mm, median (IQR) 18 (17–19.5) 
TST negative, n (%) 0 (0) 
TST positive, n (%) 5 (100)b
AFB, acid-fast bacillus; BCG, bacille Calmette–Gue´rin; BMI, body mass index; IQR, interqu
test.
a Active TB group: Langerhans cell histiocytosis, thyroid cancer, non-small cell lung 
b Available for ﬁve patients.mitogen, and incubated for 20 h at 37 8C. The plasma supernatant
was collected after centrifugation and stored frozen at 20 8C until
assayed. The concentration of IFN-g was determined using a QFT
ELISA. Results were calculated using QFT-GIT software provided by
the manufacturer. To facilitate comparisons with IP-10 levels, IFN-
g results are presented in pg/ml. According to previous studies, one
international unit (IU) of IFN-g corresponds to 50 pg/ml.5,8,17
2.2.3. IP-10 determination
The IP-10 level was measured in duplicate in supernatants
collected from the plasma of QFT-GIT tubes and in sera from all
participants, using a commercial ELISA in accordance with the
manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA).
The upper limit of IP-10 for the assay was set at 20 000 pg/ml.
2.3. Data analysis
Data are expressed as number (percentage) or median and
interquartile range (IQR), and non-parametric analyses were used
because the majority of the data did not follow a normal
distribution. Categorical variables were analyzed using Pearson’s
Chi-square test or Fisher’s exact test. Continuous variables were
analyzed using the Kruskal–Wallis test with the Bonferroni
correction for multiple comparisons. The most appropriate cut-
off values for serum IP-10 and antigen-stimulated IP-10 for the
detection of active TB disease were established by receiver
operating characteristic (ROC) curve analysis to maximize the
sum of the sensitivity and speciﬁcity. TB antigen-dependent
cytokine secretion was determined as the difference in cytokine
levels between the control tube and the TB antigen-coated tube.7 A
p-value of 0.05 was taken to indicate a signiﬁcant difference. All
data were analyzed using GraphPad Prism (GraphPad, San Diego,
CA, USA) and SPSS (v. 18.0; SPSS, Chicago, IL, USA).
3. Results
3.1. Characteristics of the participants
The study examined 46 active pulmonary TB patients, 22
subjects with LTBI, and 32 non-TB controls. Table 1 presents theLTBI group
(n = 22)
Non-TB group
(n = 32)
37.5 (22–53) 28 (22–57)
4/18 14/18
21.82 (19.6–23.9) 22.42 (20.2–24.5)
20 (90.9) 24 (75)
1 (4.5) 0 (0)
0 (0) 1 (3.1)
0 (0) 1 (3.1)
2 (9.1) 1 (3.1)
16 (13–21.5) 0 (0–2.75)
0 (0) 32 (100)
22 (100) 0 (0)
artile range; LTBI, latent tuberculosis infection; TB, tuberculosis; TST, tuberculin skin
cancer, colon cancer. LTBI group: breast cancer, endometrial cancer.
Table 2
IFN-g and IFN-g IP-10 release after antigen stimulation, and serum IP-10 levels in active TB, latent TB, and non-TB control groups
Test Active TB group
(n = 46)
LTBI group
(n = 22)
Non-TB group
(n = 32)
p-Valuea
IFN-g
Nil 9 (3.0–15.3) 12.3 (4.1–36.1) 5 (3–11.3) 0.094
TB antigen 352 (171.1–500) 148.8 (96.9–500) 8.5 (2.6–19.5) <0.001b
IP-10
Nil 1176 (664.8–2444) 2248 (750.2–12010) 491.0 (207.2–1588) 0.001c
TB antigen 20 000 (13 858–20 000) 20 000 (17 076–20 000) 963.3 (479.2–2619) <0.001d
Serum IP-10 174.9 (123.8–368.4) 102.7 (72.9–144.5) 71.14 (60.1–111.8) <0.001e
IFN-g, interferon gamma; IP-10, inducible protein 10; LTBI, latent tuberculosis infection; TB, tuberculosis.
Data are presented as the median concentration in pg/ml (interquartile range).
a p-Value in the table is the result of a Kruskal–Wallis analysis comparing the groups all together.
b p = 0.10 for active TB vs. LTBI; p < 0.001 for active TB vs. non-TB; p < 0.001 for LTBI vs. non-TB.
c p = 0.133 for active TB vs. LTBI; p = 0.033 for active TB vs. non-TB; p = 0.004 for LTBI vs. non-TB.
d p = 1.0 for active TB vs. LTBI; p < 0.001 for active TB vs. non-TB; p < 0.001 for LTBI vs. non-TB.
e p = 0.002 for active TB vs. LTBI; p < 0.001 for active TB vs. non-TB; p = 0.047 for LTBI vs. non-TB.
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gender distributions among the three groups were not different.
Nine patients (19.6%) in the active TB group were AFB smear-
positive. TST results were available for ﬁve patients in the active TB
group, and all ﬁve were positive.
3.2. Measurement of IP-10 and IFN- g
Table 2 shows IP-10 and IFN-g following antigen stimulation in
the active TB, LTBI, and non-TB control groups. The median IFN-g
and IP-10 responses to TB antigen were signiﬁcantly greater in the
active TB and LTBI groups than in the non-TB group. Neither the IP-
10 nor IFN-g response to TB antigen differed signiﬁcantly between
the active TB and LTBI groups (IP-10: p = 1.0; IFN-g: p = 0.10). The
IP-10 response in the nil-tube was different among the three
groups. The IP-10 responses to nil in the active TB and LTBI groups
were signiﬁcantly higher than in the non-TB control group.
As shown in Figure 1, TB-speciﬁc antigen-dependent IP-10 was
signiﬁcantly higher in the active TB and LTBI groups compared
with the non-TB control group, while there was no difference
between the active TB and LTBI groups for IFN- g (IP-10: p = 0.182;
IFN-g: p = 0.072).
The serum IP-10 level differed signiﬁcantly among the three
groups. The serum IP-10 was signiﬁcantly higher in active TB
patients (median 174.9 pg/ml; IQR 123.8–368.4) than in LTBIFigure 1. Distribution of IP-10 and IFN-g responses to Mycobacterium tuberculosis-speciﬁ
indicate median values. *, active TB; &, LTBI; ~, non-TB controls. TB Ag-nil: M. tuber
between the nil tube and TB antigen-coated tube. IP-10, IFN-g inducible protein 10
QuantiFERON1-TB Gold In-Tube assay.subjects (median 102.7 pg/ml; IQR 72.9–144.5; p < 0.05) and non-
TB subjects (median 71.14 pg/ml; IQR 60.1–111.8; p < 0.001).
3.3. Diagnostic usefulness of serum IP-10 and antigen-dependent IP-
10 (IP-10 TB-nil)
To evaluate the usefulness of IP-10 in the diagnosis of TB-
speciﬁc infection, we performed a ROC analysis of serum IP-10 and
the antigen-dependent IP-10 response, comparing the active TB
and non-TB groups. We selected cut-off points to maximize the
sum of the sensitivity and speciﬁcity. The cut-off points for best
performance were 119.5 pg/ml for serum IP-10 (sensitivity 87.5%,
95% conﬁdence interval (CI) 67.6–97.3; speciﬁcity 90.5%, 95% CI
69.6–98.8; area under the curve 0.93, 95% CI 0.86–1.00; p < 0.001)
(Figure 2a) and 2811 pg/ml for TB antigen-dependent IP-10
(sensitivity 97.8%, 95% CI 88.5–99.9; speciﬁcity 87.5%, 95% CI 71.0–
96.5; area under the curve 0.96, 95% CI 0.91–1.01; p < 0.001)
(Figure 2b). The proportion of positive responders was compared
among the active TB, LTBI, and non-TB control groups using the
selected cut-offs for IP-10 and IFN-g (Table 3). Based on serum IP-
10, the proportions of positive responders were 87.5%, 45.5%, and
9.5% in the active TB, LTBI, and non-TB control groups, respectively.
Based on TB antigen-stimulated IP-10, the proportions of positive
responders were 97.8%, 90.9%, and 12.5% in the respective groups.
These responses are comparable to the positive results of thec antigen in QFT-GIT assays, in active TB, LTBI, and non-TB groups. Horizontal lines
culosis antigen-dependent response measured as the difference in cytokine levels
; TB, tuberculosis; LTBI, latent TB infection; IFN-g, interferon gamma; QFT-GIT,
Figure 2. ROC curve showing the accuracy of IP-10 in the diagnosis of Mycobacterium tuberculosis infection. (a) Levels detected in serum and (b) Mycobacterium tuberculosis-
speciﬁc levels after background correction. ROC curve analysis was performed using active TB patients and non-TB controls for comparison.
(a) AUC 0.93 (95% CI 0.86–1.0), p < 0.001 for serum IP-10; (b) AUC 0.96 (95% CI 0.91–1.01), p < 0.001 for Mycobacterium tuberculosis antigen-dependent IP-10 release. ROC,
receiver operating characteristics; IP-10, IFN-g inducible protein 10; AUC, area under the curve; CI, conﬁdence interval.
Table 3
Diagnostic usefulness of IFN-g and IFN-g IP-10 release after antigen stimulation, and serum IP-10
Test Active TB group
(n = 46)
LTBI group
(n = 22)
Non-TB group
(n = 32)
p-Value
QTF-GIT, n (%) <0.001
Positive 44 (95.7) 20 (90.9) 4 (12.5)
Negative 2 (4.3) 2 (9.1) 28 (87.5)
IP-10 release after TB antigen stimulation
(2811 pg/ml), n (%)
<0.001
Positive 45 (97.8) 20 (90.9) 4 (12.5)
Negative 1 (2.2) 2 (9.1) 28 (87.5)
Serum IP-10 (119.5 pg/ml), n (%)a <0.001
Positive 21 (87.5) 10 (45.5) 2 (9.5)
Negative 3 (12.5) 12 (54.5) 19 (90.5)
IFN-g, interferon gamma; IP-10, inducible protein 10; LTBI, latent tuberculosis infection; QFT-GIT, QuantiFERON1-TB Gold In-Tube assay; TB, tuberculosis.
a Serum IP-10 was measured in 24 active TB patients and in 21 of the non-TB group.
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in non-TB controls). In addition, there was very high agreement
between the QFT-GIT and antigen-stimulated IP-10 test (91%,
k = 0.79, p < 0.001).
4. Discussion
This study demonstrates that IP-10 is a useful immunodiag-
nostic marker of M. tuberculosis infection in an area with an
intermediate TB burden. We conﬁrmed previous ﬁndings that IP-
10 was secreted at high levels following M. tuberculosis-speciﬁc
antigen stimulation after TB infection, in a similar manner to IFN-
g.7,15 However, the TB-speciﬁc IP-10 response could not differen-
tiate the active TB group from the LTBI group.
The production of IP-10, a member of the CC chemokines, is
increased in monocytes and polymorphonuclear granulocytes
following M. tuberculosis infection.18 Increased IP-10 levels have
also been identiﬁed in autoimmune disorders, including systemic
lupus erythematosus,19 autoimmune hepatitis, primary biliary
cirrhosis,20 bronchial asthma,21 and atopic dermatitis.22
Distinct from the assumption that IP-10 may reﬂect only
inﬂammation and may be too non-speciﬁc to be used alone in
diagnosing TB, Ruhwald et al. reported that the IP-10 response to
M. tuberculosis-speciﬁc antigen could be used to diagnose TB
infection.5 Similarly, the present study demonstrated that the area
under the ROC curve for TB antigen-stimulated IP-10 (0.96, 95% CI
0.91–1.01; p < 0.001) was as high as that for IFN-g (0.97, 95% CI
0.93–1.01; p < 0.001). The sensitivity was similar between IFN-gand TB antigen-stimulated IP-10 in active TB patients (Table 3), but
TB antigen-stimulated IP-10 was not able to discriminate between
active and latent TB infection. Our results agree with previous
studies demonstrating that the IP-10 response to RD1 selected
antigen did not differ signiﬁcantly between active and latent TB
infection.23
Our results showed higher background IP-10 levels in whole
blood from LTBI subjects compared with active TB and non-TB
subjects. Whittaker et al.7 and Lighter et al.8 reported similar
ﬁndings in children. This could be explained by the presence of a
chronic inﬂammation state, evoking the recruitment of neutro-
phils, monocytes, and Th1 lymphocytes to control TB infection in
LTBI subjects. Chen et al. showed that the levels of unstimulated IP-
10 in the control tubes paralleled the occurrence of active TB and
the clinical remission of TB after anti-tuberculosis treatment in
rheumatoid arthritis patients.15 Whether high levels of unstimu-
lated IP-10 in whole blood during LTBI can serve as an additional
marker to predict the disease status of TB requires further
evaluation.
It is worth noting the differences in serum IP-10 levels and in M.
tuberculosis-antigen stimulated IP-10 levels among the three
different TB groups. The serum values are the circulating cytokine
levels at a given time-point, and the M. tuberculosis-stimulated
levels reﬂect the potential for M. tuberculosis reactivity by
circulating mononuclear cells. Thus, the higher level of serum
IP-10 in the active TB group compared with the LTBI group
represents the progressing inﬂammatory state of active TB
patients. However, serum IP-10 can be elevated in a number of
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the serum IP-10 level alone is insufﬁcient for diagnosing active TB.
In addition, the serum IP-10 positive response in the LTBI group in
our study was 45.5%, which was lower than that of TB antigen-
dependent IP-10 or QFT-GIT. Therefore, serum IP-10 might weakly
reﬂect M. tuberculosis-speciﬁc infection as a single marker.
According to the results, TB antigen-dependent IP-10 or QFT-GIT
cannot differentiate active TB from LTBI and are not clinically
useful for the diagnosis of TB disease in high TB burden settings due
to the high prevalence of LTBI.
This study had some limitations. First, the sample size was too
small to allow deﬁnitive conclusions and to establish cut-off
points. Second, we used the TST to deﬁne LTBI. Since BCG
vaccination is mandatory in our area, deﬁning LTBI by TST might
have compromised the speciﬁcity of selection of the LTBI group.
However, we selected the participants in the LTBI group from those
who had close contact with active pulmonary TB and 91% of them
had positive QFT-GIT results. Third, we recruited a healthy group of
LTBI and a non-TB control group and compared their IP-10 levels
with those of the active TB group. Consequently, we were unable to
estimate the clinical efﬁcacy of IP-10 for the diagnosis of active TB
in practice. A larger prospective study with active TB suspects
would be required to validate the performance of IP-10 in the
clinic. Furthermore, the active TB group included only culture-
proven pulmonary TB patients without HIV infection. Although the
serum IP-10 cut-off in this study (119.5 pg/ml) was similar to the
value (132.8 pg/ml) in a previous study,24 the cut-off for TB
antigen-stimulated IP-10 release (2811 pg/ml) was higher than
reported values of 300 pg/ml25 and 673 pg/ml.26 The discordance
among these levels may be attributable to the different disease
activities of patients or the effects of additional factors such as
geographic location, ethnicity, and technical factors. Further
studies in diverse well-deﬁned patient populations are required
to elucidate the diagnostic efﬁcacy of IP-10 and to improve the
diagnosis of TB by combining IP-10 and IFN-g assay results.
In conclusion, although the IP-10 level does not appear to be
superior to that of IFN-g as a tool for TB diagnosis, the IP-10
response to TB antigen may represent a speciﬁc biomarker for TB
infection, but does not by itself distinguish between active TB and
LTBI. The serum IP-10 level may exhibit enhanced diagnostic
performance when used in combination with another marker.
Further studies in more diverse populations are required to
validate the use of IP-10 as a diagnostic marker for TB.
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